Skip to content

Study · Animal study (in vivo) · mus musculus · 2005

11 results

Short-term continuous infusion of human parathyroid hormone 1-34 fragment is catabolic with decreased trabecular connectivity density accompanied by hypercalcemia in C57BL/J6 mice.

Iida-Klein A, Lu SS, Kapadia R, Burkhart M, Moreno A, Dempster DW, Lindsay R

The Journal of endocrinology1 Sept 2005Cited by 50 (Europe PMC)

PMID16135674 (opens in a new tab)DOI10.1677/joe.1.06270 (opens in a new tab)PepBankPUB-16135674
Source linkPubMedAsk about this study
Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

10 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Pharmacokinetics

    In mice, exogenous hPTH1-34 was detected only with PTH infusion.

    In plain wordsIn mice, the infused hormone was detected only in animals receiving hPTH1-34.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseDetection of exogenous hPTH1-34
    Study

    Mus musculusn: not reported in source

    Female C57BL/J6 mice
    Comparator
    Vehicle
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    40 microg/kg per day · continuous infusion · 2 weeksAs given in this study (Mus musculus).

    Source sentences

    Summary
    Exogenous hPTH1-34 was detected only in the PTH-infused mice.
    2 context sentences
    Summary · context
    We treated 10-week-old female C57BL/J6 mice with continuous infusion of hPTH1-34 (8.1 pmol/0.25 microl per h, equivalent to 40 microg/kg per day) or vehicle for 2 weeks, using Alzet osmotic pumps.
    Summary · context
    Separately, we compared the effects of intermittent daily injection of hPTH1-34 (40 microg/kg per day) with continuous infusion of hPTH1-34 on BMD and bone markers.
  2. 02AnimalAnimal study (in vivo)Mechanism

    In mice, intermittent hPTH1-34 markedly suppressed endogenous intact PTH.

    In plain wordsIn mice, intermittent hPTH1-34 suppressed the body's own intact parathyroid hormone.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseEndogenous intact PTH suppression with intermittent dosing
    Study

    Mus musculusn: not reported in source

    Female C57BL/J6 mice
    Comparator
    Vehicle
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    40 microg/kg per day · daily injectionAs given in this study (Mus musculus).

    Source sentences

    Summary
    Both intermittent and continuous treatment with hPTH1-34 markedly suppressed endogenous mPTH1-84, but only the latter induced hypercalcemia.
    2 context sentences
    Summary · context
    We treated 10-week-old female C57BL/J6 mice with continuous infusion of hPTH1-34 (8.1 pmol/0.25 microl per h, equivalent to 40 microg/kg per day) or vehicle for 2 weeks, using Alzet osmotic pumps.
    Summary · context
    Separately, we compared the effects of intermittent daily injection of hPTH1-34 (40 microg/kg per day) with continuous infusion of hPTH1-34 on BMD and bone markers.
  3. 03AnimalAnimal study (in vivo)Mechanism

    In mice, continuous hPTH1-34 markedly suppressed endogenous intact PTH.

    In plain wordsIn mice, continuous hPTH1-34 suppressed the body's own intact parathyroid hormone.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseEndogenous intact PTH suppression with continuous dosing
    Study

    Mus musculusn: not reported in source

    Female C57BL/J6 mice
    Comparator
    Vehicle
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    40 microg/kg per day · continuous infusion · 2 weeksAs given in this study (Mus musculus).

    Source sentences

    Summary
    Both intermittent and continuous treatment with hPTH1-34 markedly suppressed endogenous mPTH1-84, but only the latter induced hypercalcemia.
    2 context sentences
    Summary · context
    We treated 10-week-old female C57BL/J6 mice with continuous infusion of hPTH1-34 (8.1 pmol/0.25 microl per h, equivalent to 40 microg/kg per day) or vehicle for 2 weeks, using Alzet osmotic pumps.
    Summary · context
    Separately, we compared the effects of intermittent daily injection of hPTH1-34 (40 microg/kg per day) with continuous infusion of hPTH1-34 on BMD and bone markers.
  4. 04AnimalAnimal study (in vivo)Safety outcome

    In mice, continuous hPTH1-34 induced hypercalcemia.

    In plain wordsIn mice, continuous hPTH1-34 caused high blood calcium.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseHypercalcemia with continuous dosing
    Study

    Mus musculusn: not reported in source

    Female C57BL/J6 mice
    Comparator
    Vehicle
    Outcome group
    Adverse events · Endocrine and hormones
    Studied dose
    40 microg/kg per day · continuous infusion · 2 weeksAs given in this study (Mus musculus).

    Source sentences

    Summary
    Both intermittent and continuous treatment with hPTH1-34 markedly suppressed endogenous mPTH1-84, but only the latter induced hypercalcemia.
    2 context sentences
    Summary · context
    We treated 10-week-old female C57BL/J6 mice with continuous infusion of hPTH1-34 (8.1 pmol/0.25 microl per h, equivalent to 40 microg/kg per day) or vehicle for 2 weeks, using Alzet osmotic pumps.
    Summary · context
    Separately, we compared the effects of intermittent daily injection of hPTH1-34 (40 microg/kg per day) with continuous infusion of hPTH1-34 on BMD and bone markers.
  5. 05AnimalAnimal study (in vivo)Safety outcome

    In mice, intermittent hPTH1-34 did not induce hypercalcemia.

    In plain wordsIn mice, intermittent hPTH1-34 did not cause high blood calcium.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeHypercalcemia with intermittent dosing
    Study

    Mus musculusn: not reported in source

    Female C57BL/J6 mice
    Comparator
    Vehicle
    Outcome group
    Adverse events · Endocrine and hormones
    Studied dose
    40 microg/kg per day · daily injectionAs given in this study (Mus musculus).

    Source sentences

    Summary
    Both intermittent and continuous treatment with hPTH1-34 markedly suppressed endogenous mPTH1-84, but only the latter induced hypercalcemia.
    2 context sentences
    Summary · context
    We treated 10-week-old female C57BL/J6 mice with continuous infusion of hPTH1-34 (8.1 pmol/0.25 microl per h, equivalent to 40 microg/kg per day) or vehicle for 2 weeks, using Alzet osmotic pumps.
    Summary · context
    Separately, we compared the effects of intermittent daily injection of hPTH1-34 (40 microg/kg per day) with continuous infusion of hPTH1-34 on BMD and bone markers.
  6. 06AnimalAnimal study (in vivo)Mechanism

    In mice, daily hPTH1-34 significantly increased serum osteocalcin.

    In plain wordsIn mice, daily hPTH1-34 increased a bone formation marker.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseOsteocalcin with intermittent dosing
    Study

    Mus musculusn: not reported in source

    Female C57BL/J6 mice
    Comparator
    Vehicle
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    40 microg/kg per day · daily injectionAs given in this study (Mus musculus).

    Source sentences

    Summary
    Daily PTH injection significantly increased both serum osteocalcin and mTRAP, while continuous PTH infusion showed a strong trend to stimulate mTRAP, with a slight but non-significant increase in osteocalcin.
    2 context sentences
    Summary · context
    We treated 10-week-old female C57BL/J6 mice with continuous infusion of hPTH1-34 (8.1 pmol/0.25 microl per h, equivalent to 40 microg/kg per day) or vehicle for 2 weeks, using Alzet osmotic pumps.
    Summary · context
    Separately, we compared the effects of intermittent daily injection of hPTH1-34 (40 microg/kg per day) with continuous infusion of hPTH1-34 on BMD and bone markers.
  7. 07AnimalAnimal study (in vivo)Mechanism

    In mice, daily hPTH1-34 significantly increased serum mTRAP activity.

    In plain wordsIn mice, daily hPTH1-34 increased a bone resorption marker.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreasemTRAP with intermittent dosing
    Study

    Mus musculusn: not reported in source

    Female C57BL/J6 mice
    Comparator
    Vehicle
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    40 microg/kg per day · daily injectionAs given in this study (Mus musculus).

    Source sentences

    Summary
    Daily PTH injection significantly increased both serum osteocalcin and mTRAP, while continuous PTH infusion showed a strong trend to stimulate mTRAP, with a slight but non-significant increase in osteocalcin.
    2 context sentences
    Summary · context
    We treated 10-week-old female C57BL/J6 mice with continuous infusion of hPTH1-34 (8.1 pmol/0.25 microl per h, equivalent to 40 microg/kg per day) or vehicle for 2 weeks, using Alzet osmotic pumps.
    Summary · context
    Separately, we compared the effects of intermittent daily injection of hPTH1-34 (40 microg/kg per day) with continuous infusion of hPTH1-34 on BMD and bone markers.
  8. 08AnimalAnimal study (in vivo)Mechanism

    In mice, continuous hPTH1-34 showed a strong trend toward increased mTRAP activity.

    In plain wordsIn mice, continuous hPTH1-34 showed a trend toward increasing a bone resorption marker.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreasemTRAP with continuous dosing
    Study

    Mus musculusn: not reported in source

    Female C57BL/J6 mice
    Comparator
    Vehicle
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    40 microg/kg per day · continuous infusion · 2 weeksAs given in this study (Mus musculus).

    Source sentences

    Summary
    Daily PTH injection significantly increased both serum osteocalcin and mTRAP, while continuous PTH infusion showed a strong trend to stimulate mTRAP, with a slight but non-significant increase in osteocalcin.
    2 context sentences
    Summary · context
    We treated 10-week-old female C57BL/J6 mice with continuous infusion of hPTH1-34 (8.1 pmol/0.25 microl per h, equivalent to 40 microg/kg per day) or vehicle for 2 weeks, using Alzet osmotic pumps.
    Summary · context
    Separately, we compared the effects of intermittent daily injection of hPTH1-34 (40 microg/kg per day) with continuous infusion of hPTH1-34 on BMD and bone markers.
  9. 09AnimalAnimal study (in vivo)Mechanism

    In mice, continuous hPTH1-34 produced a slight, nonsignificant increase in osteocalcin.

    In plain wordsIn mice, continuous hPTH1-34 did not significantly increase osteocalcin.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeOsteocalcin with continuous dosing
    Study

    Mus musculusn: not reported in source

    Female C57BL/J6 mice
    Comparator
    Vehicle
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    40 microg/kg per day · continuous infusion · 2 weeksAs given in this study (Mus musculus).

    Source sentences

    Summary
    Daily PTH injection significantly increased both serum osteocalcin and mTRAP, while continuous PTH infusion showed a strong trend to stimulate mTRAP, with a slight but non-significant increase in osteocalcin.
    2 context sentences
    Summary · context
    We treated 10-week-old female C57BL/J6 mice with continuous infusion of hPTH1-34 (8.1 pmol/0.25 microl per h, equivalent to 40 microg/kg per day) or vehicle for 2 weeks, using Alzet osmotic pumps.
    Summary · context
    Separately, we compared the effects of intermittent daily injection of hPTH1-34 (40 microg/kg per day) with continuous infusion of hPTH1-34 on BMD and bone markers.
  10. 10AnimalAnimal study (in vivo)Mechanism

    In mice, hPTH1-34 infusion significantly decreased distal femoral trabecular connectivity density versus vehicle.

    In plain wordsIn mice, hPTH1-34 infusion reduced connections within spongy bone versus vehicle.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseTrabecular connectivity density
    Study

    Mus musculusn: not reported in source

    Female C57BL/J6 mice
    Comparator
    Vehicle
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    40 microg/kg per day · continuous infusion · 2 weeksAs given in this study (Mus musculus).

    Source sentences

    Summary
    Micro-computed tomography (muCT) analysis of the distal femurs revealed that hPTH1-34 infusion significantly decreased trabecular connectivity density (P<0.05).
    2 context sentences
    Summary · context
    We treated 10-week-old female C57BL/J6 mice with continuous infusion of hPTH1-34 (8.1 pmol/0.25 microl per h, equivalent to 40 microg/kg per day) or vehicle for 2 weeks, using Alzet osmotic pumps.
    Summary · context
    Separately, we compared the effects of intermittent daily injection of hPTH1-34 (40 microg/kg per day) with continuous infusion of hPTH1-34 on BMD and bone markers.

Studies that did not test the peptide alone1

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

  1. 11AnimalNot a test of Teriparatide (PTH 1-34) aloneAnimal study (in vivo)Mechanism

    In mice, BMD at all measured sites differed significantly between continuous and intermittent hPTH1-34 at the same daily dose.

    In plain wordsIn mice, bone density differed between continuous and intermittent hPTH1-34 at the same daily dose.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    Direction not reportedBMD across sites by dosing pattern
    Study

    Mus musculusn: not reported in source

    Female C57BL/J6 mice
    Comparator
    Intermittent hPTH1-34 at the same daily dose
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    There were significant differences in BMD at all sites between animals treated with the same daily dose of intermittent and continuous hPTH1-34.
    2 context sentences
    Summary · context
    We treated 10-week-old female C57BL/J6 mice with continuous infusion of hPTH1-34 (8.1 pmol/0.25 microl per h, equivalent to 40 microg/kg per day) or vehicle for 2 weeks, using Alzet osmotic pumps.
    Summary · context
    Separately, we compared the effects of intermittent daily injection of hPTH1-34 (40 microg/kg per day) with continuous infusion of hPTH1-34 on BMD and bone markers.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.